BioWorld

May 2, 2007

View Archived Issues

Series A And B Rounds Up As Early Stage Model Evolves

Of the $2.1 billion in venture capital invested in global biotechnology companies last quarter, the majority went into earlier-stage financings, according to data from BioWorld Financial Watch and BioWorld Snapshots. (BioWorld Today) Read More

House Hearing Probes Range Of Ways To Improve The FDA

Read More

Optimer's CDAD Drug Starts Second Pivotal Phase III Trial

Read More

NewCo News: Start-Up Solace Raises $15M In Series A For Pain Drugs

Read More

Italian Firm Eurand Files For IPO On Nasdaq Of Up To $153M

Read More

Other News To Note

Read More

Clinic Roundup

Read More